MA-NEC-ENERGY-SOLUTIONS
14.1.2020 14:02:10 CET | Business Wire | Press release
NEC Energy Solutions, Inc. (NEC ES), announced today it will provide 100MW of energy storage in Northern Ireland for the Gore Street Energy Storage Fund (GSF) and project developer Low Carbon. The 100MW of energy storage will comprise two 50MW projects located in Drumkee, County Tyrone and Mullavilly, County Armagh. The two projects, which are currently under construction, are the largest projects to date in Northern Ireland and are expected to derive revenue from the new Irish “Delivering a Secure Sustainable Electricity System” (DS3) program.
The System Operator of Northern Ireland has indicated that running the power system with increasingly high levels of renewable energy is a major challenge due to the intermittent nature of wind power and its technical characteristics. The purpose of the DS3 program is to enable Ireland to meet its target of 75% non-synchronous and renewable (i.e. wind and solar) electricity across the all-island network. The DS3 market consists of both fixed and standard contracts available across the Irish grid in both the Republic of Ireland and Northern Ireland.
“Northern Ireland has made tremendous progress adopting renewable energy. Last year 44% of electricity consumption was generated by renewable resources. This easily beats Northern Ireland’s renewable target of 40% and occurred one year ahead of its 2020 deadline. Energy storage, via the DS3 program makes more of this possible”, said Steve Fludder, CEO of NEC Energy Solutions. “We are pleased to extend our partnership with Gore Street Capital. We invested in the Gore Street Energy Storage Fund and we look forward to working with Gore Street Capital on these and future projects. We also have excellent experience with Low Carbon operating and maintaining their two projects in the UK and we’re eager to collaborate with them in Northern Ireland.”
NEC is providing turnkey engineering, procurement and construction (EPC) including its GSS® end-to-end grid storage solution and its AEROS® controls system, NEC’s proprietary energy storage control software. Both 50MW projects will be completed and commissioned in Q1 2021. This transaction marks the second tranche of projects that NEC has been awarded by both Gore Street and Low Carbon.
“We are pleased to award this important EPC contract to NEC Energy Solutions, one of Gore Street’s long-term strategic partners, following a significant competitive tender process. We chose NEC Energy Solutions because they have offered the optimal commercial and technical proposal,” commented Alex O’Cinneide, CEO of Gore Street Capital, the investment manager of Gore Street Energy Storage Fund PLC. “We look forward to working once again with NEC Energy Solutions on these significant projects, among the largest of their kind in Ireland. As investment in sources of volatile renewable generation to supply the grid in Ireland continues to increase, supported in particular by excellent wind generation potential, assets such as these will form a major step in advancing Ireland’s climate change objectives.”
About NEC Energy Solutions
NEC Energy Solutions designs, manufactures, and integrates smart energy storage solutions for the electric grid and applications with critical power needs. Its megawatt-scale energy storage and control systems provide greater stability to the grid while maximizing renewable generation, while in telecom, datacenter, and other industrial applications, its high performance lithium-ion battery systems provide better value than traditional lead-acid batteries in tough, critical power applications. Learn more at www.neces.com .
About Gore Street Energy Storage Fund Plc.
Gore Street Energy Storage Fund is the first publicly traded fund established to provide investors with a sustainable and attractive dividend over the long term by investing in a diversified portfolio of utility scale energy storage projects primarily located in the UK, North America and Western Europe. The fund went public on May 25, 2018 on the London Stock Exchange.
About Gore Street Capital
GSC is a private equity firm with a leading renewable investment expertise. Established in 2013, GS has provided a platform to acquire, develop and manage global renewable energy and has a highly experience management team. Gore Street has some energy storage experience – they have been behind the Cleveland Potash project in North Yorkshire, the Lower Road project in Brentwood, Essex and the Port of Tilbury project co-located with London’s Port of Tilbury. All projects included NEC Energy Solutions hardware and software.
NEC is a registered trademark of NEC Corporation. All Rights Reserved. Other product or service marks mentioned herein are the trademarks of their respective owners.
©2020 NEC Corporation
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005403/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom